Comparisons
The study groups at Saline Peptides
Three peptide names make a tidy list. Their experiments make a much less tidy contest. I prefer to ask which question each group of subjects actually faced.
Treatment comparisons
The natural temptation is to rank these compounds from weakest to strongest. I think that would obscure more than it explains. A faster-growing rat bone, a blood-hormone pulse and weight loss in adults concern different bodies, measurements and ambitions.
| Experiment | Comparison | Measured result |
|---|---|---|
| Ipamorelin in bowel-surgery patients | Ipamorelin versus placebo | First tolerated meal: 25.3 versus 32.6 hours; primary endpoint missed |
| Ipamorelin in adult female rats | Study arms versus vehicle | Bone growth: 44, 50 and 52 versus 42 micrometers/day |
| MOTS-c in mice | Administered peptide in animal performance experiments | Improved running capacity, grip strength and gait in aged mice |
| Retatrutide in adults with obesity | Highest study arm versus placebo | Mean body-weight reduction at 48 weeks: 24.2% versus 2.1% |
There is no shared unit that makes these outcomes interchangeable. Even the two human randomized trials asked different clinical questions.
The observational comparison
The MOTS-c hemodialysis cohort needs its own space. It compared naturally circulating peptide measurements with subsequent outcomes. Nobody was allocated MOTS-c as a treatment. A useful risk marker would earn my respect; its usefulness would still leave the treatment question open.
That separation also helps with the biological stories. Ipamorelin stimulates growth-hormone release; MOTS-c participates in cellular metabolic and stress responses; retatrutide activates three hormone receptors. Similar enthusiasm around their names does little to align those mechanisms.
Safety and status across the three
All three lack FDA approval. Retatrutide remains investigational in Phase 3 development with lawful clinical access restricted to registered trials. MOTS-c has a clinician-assessed prescription route alongside research-labelled supply; an individual prescription decision supplies no clinical-trial result. Ipamorelin’s human safety record remains brief, and MOTS-c lacks completed human interventional safety data.
The heart-rate and gastrointestinal findings in retatrutide trials command my respect as observations in people receiving the compound. The rat-heart injury finding in a different ghrelin agonist raises a class-level question for ipamorelin while leaving its own chronic safety unresolved. These are different kinds of concern, and neither improves with a blanket assurance about peptides.